Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.
Anhui Anke Biotechnology Dividend Announcement
• Anhui Anke Biotechnology announced a annually dividend of ¥0.25 per ordinary share which will be made payable on 2024-05-27. Ex dividend date: 2024-05-27
• Anhui Anke Biotechnology annual dividend for 2024 was ¥0.25
• Anhui Anke Biotechnology annual dividend for 2023 was ¥0.25
• Anhui Anke Biotechnology's trailing twelve-month (TTM) dividend yield is 2.57%
• Anhui Anke Biotechnology's payout ratio for the trailing twelve months (TTM) is 105.84%
• Anhui Anke Biotechnology's dividend growth over the last five years (2018-2023) was 10.76% year
• Anhui Anke Biotechnology's dividend growth over the last ten years (2013-2023) was 0.26% year
Anhui Anke Biotechnology Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-05-27 | ¥0.25 | annually | 2024-05-27 |
2023-05-19 | ¥0.25 | annually | 2023-05-19 |
2022-05-13 | ¥0.20 | annually | 2022-05-13 |
2021-05-14 | ¥0.17 | annually | 2021-05-14 |
2020-05-22 | ¥0.15 | annually | 2020-05-22 |
2019-05-09 | ¥0.15 | annually | 2019-05-09 |
2018-05-04 | ¥0.15 | annually | 2018-05-04 |
2017-05-18 | ¥0.15 | annually | 2017-05-18 |
2016-04-15 | ¥0.15 | annually | |
2015-04-17 | ¥0.15 | annually | |
2014-06-06 | ¥0.20 | annually | |
2013-06-13 | ¥0.24 | annually |
Anhui Anke Biotechnology Dividend per year
Anhui Anke Biotechnology Dividend growth
Anhui Anke Biotechnology Dividend Yield
Anhui Anke Biotechnology current trailing twelve-month (TTM) dividend yield is 2.57%. Interested in purchasing Anhui Anke Biotechnology stock? Use our calculator to estimate your expected dividend yield:
Anhui Anke Biotechnology Financial Ratios
Anhui Anke Biotechnology Dividend FAQ
Other factors to consider when evaluating Anhui Anke Biotechnology as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Anhui Anke Biotechnology stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Anhui Anke Biotechnology's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Anhui Anke Biotechnology publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Anhui Anke Biotechnology distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Anhui Anke Biotechnology are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Anhui Anke Biotechnology sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Anhui Anke Biotechnology distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Anhui Anke Biotechnology declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Anhui Anke Biotechnology's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Anhui Anke Biotechnology's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.